Regulation of TERT in Human Pluripotent Stem Cells: MEK1/2, c-Myc:MAX, and Polycomb Repression

Study Background and Research Question

Telomerase reverse transcriptase (TERT) is essential for maintaining telomere length and long-term proliferative capacity in human embryonic stem cells (hESCs). While the catalytic action of telomerase is well studied, the transcriptional regulation of TERT in normal human stem cells remains poorly understood. Previous work has implicated mitogen-activated protein kinase (MAPK) signaling in maintaining TERT expression, but the precise mechanisms, particularly the involvement of chromatin-modifying complexes such as Polycomb repressive complex 2 (PRC2), have not been fully elucidated. The present study (Kotian et al., 2024) addresses the central question: How do MAPK pathway components and transcription factors coordinate to prevent PRC2-mediated repression of TERT in hESCs?

Key Innovation from the Reference Study

The innovation of this research lies in delineating a cooperative mechanism where MEK1/2 kinases and the c-Myc:MAX transcriptional complex actively prevent Polycomb-mediated silencing of TERT. Specifically, the authors demonstrate that MEK1/2 activity restricts PRC2-dependent deposition of the repressive histone mark H3K27me3 at the TERT promoter, maintaining TERT in a transcriptionally permissive state. Inhibition of MEK1/2 or disruption of c-Myc:MAX dimerization leads to rapid H3K27 trimethylation and TERT repression, establishing a direct chromatin-based link between growth signaling, transcription factor binding, and telomerase gene regulation (Kotian et al., 2024).

Methods and Experimental Design Insights

The authors used a combination of pharmacological inhibition, chromatin immunoprecipitation (ChIP), and transcriptional analyses in hESC models. Key methods included:

• MEK/ERK Inhibition: Selective inhibitors were applied to block MEK1/2 and ERK1/2 activity in hESCs. TERT mRNA levels and histone modification states were measured post-treatment.
• ChIP-qPCR: Chromatin immunoprecipitation was used to quantify H3K27me3 and H3K27ac enrichment at the TERT promoter, providing direct evidence of chromatin state changes.
• PRC2 Inhibition: Chemical inhibitors targeting PRC2 were applied to assess whether limiting H3K27me3 could rescue TERT expression following MEK inhibition.
• c-Myc:MAX Disruption: A specific inhibitor of c-Myc:MAX dimerization was used to dissect the role of this complex in TERT regulation, with subsequent analysis of chromatin state and transcription.

This multi-modal design allowed the authors to link upstream signaling, transcription factor binding, and epigenetic modification in a causally connected framework.

Core Findings and Why They Matter

1. MEK1/2 Activity Maintains TERT Expression via Chromatin State
Inhibition of MEK1/2 or ERK1/2 kinases in hESCs resulted in marked reduction of TERT mRNA. This repression correlated with increased H3K27me3 (a silencing mark) and reduced H3K27ac (an active mark) at the TERT promoter. This finding demonstrates a direct pathway by which MAPK signaling maintains TERT transcriptional competence through limiting PRC2-mediated chromatin repression (Kotian et al., 2024).

2. PRC2 Inhibition Partially Rescues TERT Expression
Application of PRC2 inhibitors partially restored TERT mRNA levels in the context of MEK inhibition, supporting the model that PRC2-dependent H3K27 trimethylation is a key effector of TERT silencing when MAPK signaling is abrogated. This provides functional evidence for the central role of the PRC2 complex and H3K27 trimethylation inhibition in regulating stem cell telomerase gene expression.

3. c-Myc:MAX Complex Functions in cis at TERT to Prevent Polycomb Silencing
Low-dose c-Myc:MAX dimerization inhibition rapidly increased H3K27me3 and suppressed TERT transcription. ChIP data revealed reduced MAX occupancy at the TERT promoter, suggesting that the c-Myc:MAX complex acts locally to antagonize Polycomb repression, likely by maintaining a chromatin environment permissive for transcription.

4. Integration of Signaling and Chromatin Regulation
Collectively, the data reveal a coordinated pathway where extrinsic growth signals (via MEK1/2), core transcription factors (c-Myc:MAX), and chromatin modifiers (PRC2/EZH2) converge to regulate a critical stem cell gene. These mechanisms are likely relevant for understanding telomerase regulation in development, aging, and disease states characterized by altered epigenetic landscapes.

Comparison with Existing Internal Articles

Several recent reviews and technical guides have highlighted the utility of selective EZH2 inhibitors, such as GSK343, for dissecting PRC2-mediated histone H3K27 trimethylation in cancer and stem cell models. For instance, one analysis details how GSK343 enables precise study of PRC2-dependent chromatin regulation and its impact on gene expression. Another article (see here) discusses the application of GSK343 in exploring the interplay between EZH2 activity, telomerase regulation, and DNA repair in cancer cells, while a third piece links EZH2 inhibition to modulation of telomerase and emerging therapeutic strategies. The current study adds mechanistic clarity by connecting growth signaling and c-Myc:MAX activity to Polycomb repression of TERT, reinforcing the value of pharmacological tools targeting PRC2/EZH2 for probing epigenetic gene regulation in both cancer and pluripotent cell contexts.

Limitations and Transferability

While this study establishes a clear mechanistic pathway in cultured hESCs, transferability to other stem cell types or differentiated tissues requires additional validation. The use of pharmacological inhibitors, while powerful for dissecting pathways, may have off-target effects, and genetic perturbations could complement these findings. Also, the extent to which these regulatory mechanisms operate in vivo during early embryogenesis or in adult stem cell niches remains to be determined (Kotian et al., 2024). Finally, while PRC2/EZH2 function is implicated, the role of other chromatin modifiers, co-factors, and non-coding RNAs in TERT regulation merits future investigation.

Protocol Parameters

• assay: ChIP-qPCR | value: 1–10 μg chromatin per IP | applicability: Mapping H3K27me3 and H3K27ac at TERT promoter | rationale: Standard input range for robust immunoprecipitation and locus-specific quantification | source_type: workflow_recommendation
• assay: MEK/ERK inhibitor treatment | value: 1–10 μM (compound-dependent) | applicability: Inhibition of MAPK pathway for mechanistic dissection | rationale: Typical range for selective kinase inhibition in hESCs | source_type: workflow_recommendation
• assay: PRC2/EZH2 inhibitor (e.g., GSK343) | value: 0.1–10 μM in vitro | applicability: Inhibition of H3K27me3 deposition and Polycomb repression | rationale: GSK343 shows IC50 of 4 nM for EZH2 enzymatic inhibition, but higher concentrations (e.g., 0.1–10 μM) are used in cell-based assays to ensure effective chromatin modulation (product_spec) | source_type: product_spec
• assay: c-Myc:MAX dimerization inhibitor | value: 1–10 μM | applicability: Disruption of transcription factor complex for functional studies | rationale: Range based on published small-molecule inhibitor protocols | source_type: workflow_recommendation

Research Support Resources

For researchers interested in dissecting PRC2 and EZH2 function in telomerase and chromatin regulation workflows, the selective, cell-permeable EZH2 inhibitor GSK343 (SKU A3449) provides a validated tool for in vitro applications requiring potent and selective H3K27 trimethylation inhibition (product_spec). GSK343 is widely used to model Polycomb-dependent repression and can be integrated into studies of stem cell identity, oncogenesis, or therapeutic epigenetic modulation. For additional technical insight, see mechanistic reviews and workflow strategies in this advanced analysis and this mechanistic overview.